It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Early safety insights that help you make smarter decisions delivered through tailored in vivo studies, translational expertise, and close scientific partnership.
We deliver early, flexible safety and tolerability assessment that help you make confident decision about compound progression and resource allocation.
Our non-regulatory rodent toxicology services provide insight before formal GLP studies begin, with tailored study designs that adapt to your project needs.
We work as a scientific partner guiding study design, interpreting data, and linking findings to your strategy. By identifying potential safety issues early, we help ensure your studies align with long-term goals. Our close collaboration and rapid data turnaround support agile, informed decision-making.
What We Offer
Early safety and tolerability assessments are conducted in naïve and/or relevant in vivo rodent models. These are supported by dose range-finding and maximum tolerated dose studies. We enhance translational understanding through biomarker and mechanistic investigations; all delivered through tailored study designs outside formal regulatory frameworks. By combining in vivo expertise with deep knowledge in pharmacology, pathology, and translational science, we provide a holistic view of compound safety and efficacy.
Key Benefits
Our in vivo expertise and integrated capabilities give you meaningful insights that accelerate decisions and reduce risk.
Customized Study Environments
We design study conditions to answer specific safety and tolerability questions with precision.
Comprehensive System Evaluation
Our safety assessment span multiple organs and physiological systems, giving you a complete picture.
Deeper Mechanistic Insight
We connect safety findings to mode of action and translational relevance, helping you understand the “why” behind the data.
Collaborative Partnership
We work closely with your team to ensure data generation aligns with your project goals.
Scientific Agility for Confident Decisions
By combining scientific depth with flexibility, we help you identify risks early, refine compound selection, and move forward with clarity and confidence.
The tail-immersion pain model is a well-known approach in the exploration of thermally-evoked acute pain.
Case Studies
Related Capabilities
We bring together a dynamic blend of new talent and experienced pharmaceutical industry experts from a round the world, delivering excellence across every stage of discovery.
Integrated solid form and formulation strategies reduce risk, improve stability and solubility, and accelerate progression from candidate selection to clinic.
